Fighting cancer: Rocky path for immunotherapy

High hopes that new immunotherapy drugs would prove to have benefits over toxic chemotherapy were dashed by large-scale trials, says David Crow. Pharmaceutical groups are now working on combinations of the immunotherapies and using them with chemo, but some pharma groups have suffered big losses and Wall Street has become sceptical

iTunes Stitcher audioBoom SoundCloud Overcast RSS


Copyright The Financial Times Limited 2017. All rights reserved. You may share using our article tools. Please don't copy articles from FT.com and redistribute by email or post to the web.